MiR-181b sensitizes glioma cells to teniposide by targeting MDM2.

Abstract

BACKGROUND:

Although the incidence of glioma is relatively low, it is the most malignant tumor of the central nervous system. The prognosis of high-grade glioma patient is very poor due to the difficulties in complete resection and resistance to radio-/chemotherapy. Therefore, it is worth investigating the molecular mechanisms involved in glioma drug resistance. MicroRNAs have been found to play important roles in tumor progression and drug resistance. Our previous work showed that miR-181b is involved in the regulation of temozolomide resistance. In the current study, we investigated whether miR-181b also plays a role in antagonizing the effect of teniposide.

METHODS:

MiR-181b expression was measured in 90 glioma patient tissues and its relationship to prognosis of these patients was analyzed. Cell sensitivity to teniposide was tested in 48 primary cultured glioma samples. Then miR-181b stably overexpressed U87 cells were generated. The candidate genes of miR-181b from our previous study were reanalyzed, and the interaction between miR-181b and target gene MDM2 was confirmed by dual luciferase assay. Cell sensitivity to teniposide was detected on miR-181b over expressed and MDM2 down regulated cells.

RESULTS:

Our data confirmed the low expression levels of miR-181b in high-grade glioma tissues, which is related to teniposide resistance in primary cultured glioma cells. Overexpression of miR-181b increased glioma cell sensitivity to teniposide. Through target gene prediction, we found that MDM2 is a candidate target of miR-181b. MDM2 knockdown mimicked the sensitization effect of miR-181b. Further study revealed that miR-181b binds to the 3'-UTR region of MDM2 leading to the decrease in MDM2 levels and subsequent increase in teniposide sensitivity. Partial restoration of MDM2 attenuated the sensitivity enhancement by miR-181b.

CONCLUSIONS:

MiR-181b is an important positive regulator on glioma cell sensitivity to teniposide. It confers glioma cell sensitivity to teniposide through binding to the 3'-UTR region of MDM2 leading to its reduced expression. Our findings not only reveal the novel mechanism involved in teniposide resistance, but also shed light on the optimization of glioma treatment in the future.

• Authors: Yan-chang Sun, Jing Wang, Cheng-cheng Guo, Ke Sai, Jian Wang, Fu-rong Chen, Qun-ying Yang, Yin-sheng Chen, Jie Wang, Tony Shing-shun To, Zong-ping Zhang, Yong-gao Mu, Zhong-ping Chen
• Journal: BMC cancer (BMC Cancer) Vol. 14 Pg. 611 (Aug 25 2014) ISSN: 1471-2407 [Electronic] England
• PMID: 25151861 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• MIrn181 microRNA, human
• MicroRNAs
• Teniposide
• MDM2 protein, human
• Proto-Oncogene Proteins c-mdm2

Topics

• Biomarkers, Tumor (genetics, metabolism)
• Cell Line, Tumor
• Drug Resistance, Neoplasm
• Gene Expression Regulation, Neoplastic (drug effects)
• Glioma (drug therapy, genetics, pathology)
• Humans
• MicroRNAs (genetics, metabolism)
• Prognosis
• Proto-Oncogene Proteins c-mdm2 (antagonists & inhibitors, genetics, metabolism)
• Teniposide (pharmacology)
• Tumor Cells, Cultured